	US 12,351,806 B2
	HMO production
Manos Papadakis, Brønshøj (DK); and Katrine Bych Kampmann, Valby (DK)
Assigned to GLYCOM A/S, Horsholm (DK)
Appl. No. 17/759,261
Filed by GLYCOM A/S, Hørsholm (DK)
PCT Filed Jan. 22, 2021, PCT No. PCT/EP2021/051468 § 371(c)(1), (2) Date Jul. 21, 2022, PCT Pub. No. WO2021/148611, PCT Pub. Date Jul. 29, 2021.
Claims priority of application No. PA 2020 00087 (DK), filed on Jan. 23, 2020.
Prior Publication US 2023/0046359 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/70 (2006.01); C07H 3/06 (2006.01); C12N 5/10 (2006.01); C12N 15/74 (2006.01); C12P 19/00 (2006.01); C12P 19/02 (2006.01); C12P 19/18 (2006.01)

CPC C12N 15/70 (2013.01) [C12P 19/02 (2013.01)]

18 Claims

1. A genetically modified cell capable of producing one or more Human Milk Oligosaccharides (HMOs) under fermentative conditions, wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1, or a functional homologue thereof which amino acid sequence is at least 90% identical to SEQ ID NO: 1,

wherein the functional homologue increases the total production of the one or more HMOs while reducing by-product formation or facilitates the export of the one or more HMOs out of the genetically modified cell.